news
Novo Nordisk set to acquire Emisphere for $1.8 billion
Following approval by Emisphere shareholders, Novo Nordisk will acquire the…
Following approval by Emisphere shareholders, Novo Nordisk will acquire the company for a total of $1.8 billion.
List view / Grid view
Mads Krogsgaard Thomsen
news
Concizumab haemophilia trials paused over safety concerns
The occurrence of non-fatal thrombotic events in Phase III study…
The occurrence of non-fatal thrombotic events in Phase III study participants has called into question the safety of concizumab.
news
Type 2 diabetes treatment approved for children and adolescents
The FDA has approved an injection for use in patients…
The FDA has approved an injection for use in patients aged 10-17 to treat type 2 diabetes.
news
Application to EMA filed for the approval of oral semaglutide
It has been announced that a Marketing Authorisation Application (MAA)…
It has been announced that a Marketing Authorisation Application (MAA) has been submitted to the European Medicines Agency (EMA) for oral semaglutide.
news
NovoEight® passed the review by the Committee on Drugs of Pharmaceutical Affairs in Japan
NovoEight® has passed the review by the Committee on Drugs…
18 November 2013 | By Novo Nordisk
NovoEight® has passed the review by the Committee on Drugs of Japan's Pharmaceutical Affairs and Sanitation Council...
news
Novo Nordisk receives FDA approval for FlexTouch® in the US
FlexTouch® is the latest innovation in prefilled insulin delivery systems…
1 November 2013 | By Novo Nordisk
FlexTouch® is the latest innovation in prefilled insulin delivery systems from Novo Nordisk...
news
Novoeight® (turoctocog alfa) receives approval from the FDA
“The approval of Novoeight® marks an important step in offering…
16 October 2013 | By Novo Nordisk
“The approval of Novoeight® marks an important step in offering a new alternative for people with haemophilia A..."
news
Novo Nordisk reports positive results from first phase 3 trial with long-acting factor IX for treatment of haemophilia B
Novo Nordisk announced the completion of paradigm™ 2...
17 May 2013 | By Novo Nordisk
Novo Nordisk announced the completion of paradigm™ 2...
news
People with type 2 diabetes achieve 6% weight loss with liraglutide 3 mg in phase 3a obesity trial
Novo Nordisk announced the headline results from a 56-week, double-blind…
18 March 2013 | By Novo Nordisk
Novo Nordisk announced the headline results from a 56-week, double-blind phase 3a clinical trial...
news
Tresiba® and Ryzodeg® receive marketing authorisations in Europe
“We look forward to making Tresiba® and Ryzodeg® available to…
21 January 2013 | By Novo Nordisk
“We look forward to making Tresiba® and Ryzodeg® available to many people with diabetes in Europe”
news
Insulin degludec and insulin degludec/insulin aspart receive positive vote for approval
“The positive vote from the Advisory Committee marks an important…
9 November 2012 | By Novo Nordisk
“The positive vote from the Advisory Committee marks an important step..."
news
Tresiba® and Ryzodeg® receive positive opinions from the European regulatory authorities
Tresiba® and Ryzodeg® receive positive opinions...
19 October 2012 | By Novo Nordisk
Tresiba® and Ryzodeg® receive positive opinions...
news
Novo Nordisk files for regulatory approval of turoctocog alfa for haemophilia A in the US and EU
Novo Nordisk announced the submission of the regulatory application for…
16 October 2012 | By Novo Nordisk
Novo Nordisk announced the submission of the regulatory application for turoctocog alfa...
news
Novo Nordisk to initiate phase 3 development of semaglutide
The decision to initiate the global phase 3 development programme…
21 June 2012 | By Novo Nordisk
The decision to initiate the global phase 3 development programme for semaglutide announced...
news
JDRF and Novo Nordisk establish R&D collaboration in type 1 diabetes
Focus will be on disease-modifying immunotherapies for type 1 diabetes...
13 June 2012 | By Novo Nordisk
Focus will be on disease-modifying immunotherapies for type 1 diabetes...
